Spero Therapeutics licenses anti-CD40L antibody SP001 from Innovent in deal worth about US$ 1.1 billion
SPRO•Spero licenses SP001 from Innovent in global deal
Spero Therapeutics signed an exclusive license with Innovent Biologics for SP001 (IBI355), a Phase 2-ready third-generation anti-CD40L antibody.
Spero secured global rights excluding Greater China, covering development, manufacturing, research, and commercialization.
Innovent will receive an upfront payment, up to USD 1.1 billion in milestones, and tiered royalties on net sales in Spero’s territories.
Development plans for IgG4-related disease and Sjögren’s disease
Spero plans to start a Phase 2 trial in IgG4-related disease in Q2 2027.
Innovent plans a China Phase 2 trial in Sjögren’s disease by early 2027.
